ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033

Its studies are mostly in Carcinoma, Hepatocellular, led by BeOne Medicines.

Drug pageAnti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 17, 20263 company-led studies, 3 open or runningNext primary completion: Mar 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BeOne Medicines33 open or runningphase 3since Sep 17, 2026May 20, 2024Mar 31, 2027phase 2 · NCT06427941

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 20, 2024First study: phase 2 study in Carcinoma, HepatocellularFirst studyNCT06427941 · 630 planned · United States, Brazil, China and more
  2. Sep 17, 2026Phase 3 study in Carcinoma, HepatocellularPhase 3 reachedNCT07836530 · 492 planned · Australia, New Zealand
  3. Oct 27, 2026Phase 2 study in Liver NeoplasmsNCT07911683 · 100 planned

Ahead

  1. Mar 31, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularNCT06427941
  2. Mar 31, 2028Primary completion: phase 2 study in Liver NeoplasmsNCT07911683
  3. Sep 21, 2029Primary completion: phase 3 study in Carcinoma, HepatocellularNCT07836530

TargetBeta

“A bispecific antibody directed against both the tumor-associated antigen (TAA) glypican-3 (GPC3; GPC-3) and the costimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), ”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07911683Liver Neoplasms2Not yet recruitingMar 31, 2028100
NCT07836530Carcinoma, Hepatocellular · Australia, New Zealand3RecruitingSep 21, 2029492
NCT06427941Carcinoma, Hepatocellular · United States, Brazil, China and more2RecruitingMar 31, 2027630

How it is read

Names in the registry

  • “BGB-B2033”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.